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Résumé 
Nhx1 est un antiport vacuolaire de Na+/H+ chez la levure Saccharomyces 
cerevisiae. Nhx1 joue un rôle important dans le maintien de l’homéostasie ionique du 
cytoplasme de la cellule. En effet, la mutation du gène NHX1 chez la levure 
nhx1∆ entraîne une perte de l’homéostasie cellulaire quand les cellules sont cultivées 
dans un milieu de faible osmolarité. 
Ce travail rapporte pour la première fois, et contrairement à la cellule parentale, 
que la mutation du gène NHX1 a pour effet une sensibilité du mutant nhx1∆ à une 
variété des drogues et des agents cationiques et anioniques lorsque les cellules sont 
cultivées dans un milieu riche. En outre, dans ces conditions de culture, aucune 
sensibilité n’a été observée chez le mutant nhx1∆ quand les cellules sont traitées avec 
différentes concentrations de sel. Nous avons aussi démontré que la sensibilité du 
mutant nhx1∆ aux différents agents ainsi que la sécrétion de l’enzyme carboxypeptidase 
Y observé chez ce mutant n’ont pas été restauré lorsque les cellules sont cultivées dans 
des milieux avec différents pH ou avec différentes concentrations de sel.  
Enfin, une analyse génétique a révélé que le mutant nhx1∆  montre un 
phénotype distinct d’autres mutants qui ont un défaut dans le trafic entre le 
compartiment pré-vacuolaire et l’appareil de Golgi quand ces cellules sont traitées avec 
différents agents. Cette analyse prouve que la sensibilité de nhx1∆ aux différents agents 
n’est pas liée au trafic entre le compartiment pré-vacuolaire et l’appareil de Golgi. 
 
Mots-clés: Bléomycine, Processus d’endocytose, Compartiment pré-vacuolaire, 
Appareil de Golgi. 
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Abstract 
Nhx1 is an intracellular Na+/H+ exchanger localized to the late endosome in 
Saccharomyces cerevisiae. It is believed that Nhx1 plays a major role in pH-mediated 
vesicle trafficking, as nhx1∆ mutant is defective in maintaining the intracellular pH in 
the vacuoles and cytoplasm when grown in low osmolarity media.  
In this work, we reported novel drug sensitivities of the nhx1∆ mutant to a range 
of cationic and anionic agents when cells are grown in rich media. Unlike the low 
osmolarity media, the nhx1∆ mutant showed no sensitivity to salt. Furthermore, we 
showed that the drug phenotypes of the nhx1∆ mutant, as well as the secretion of the 
vacuolar protein carboxypeptidase Y, were not rescued by either altering the pH or salt 
concentration. Although, amino acid substitution of the phylogenetically conserved 
residue Glu355 for Ala (E355A) in Nhx1 resulted in sensitivity to genotoxic drug 
bleomycin, it was not observed for the non-conserved residue Glu371Ala (E371A). 
Moreover, genetic analysis revealed that the nhx1∆ mutant displayed distinct drug 
phenotypes in comparison to mutants that are defective in retrograde trafficking from 
the prevacuole to the late Golgi, excluding the possibility that the drug sensitivity of the 
nhx1∆ mutant is related to retrograde trafficking.  
 
 
Keywords: Bleomycin, Endocytic pathway, Prevacuolar compartment, Golgi. 
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Chapter 1 Introduction 
1.1 Bleomycin 
Bleomycin is a chemotherapeutic glycopeptide antibiotic isolated from 
Streptomyces verticillis (Umezawa, 1965; Umezawa et al., 1966) and is believed to 
reduce the growth of the tumors in mice, rats and human (Ichikawa et al., 1969; Kanno 
et al., 1969; Oka et al., 1970; Suzuki et al., 1968; Terasima et al., 1970). It has been 
shown that bleomycin acts as a chemotherapeutic agent by directly damaging the DNA 
and causing cell death (Burger et al., 1981a; Burger et al., 1982; Hecht, 1986; Kane & 
Hecht, 1994). Further analysis revealed that bleomycin is involved in micronuclei 
formation as well as chromosome aberrations in human lymphocytes. It also induces 
mitotic recombination in many organisms (Hoffmann et al., 1993; Ramotar & Wang, 
2003). Since the drug creates some lesions similar to those created by ionizing radiation 
(Burger, 1998; Worth et al., 1993), it is known as radiomimetic agent (Absalon et al., 
1995a; Dedon & Goldberg, 1992; Hoehn et al., 2001; Steighner & Povirk, 1990a; 
Steighner & Povirk, 1990b).  
Bleomycin is efficient against lymphomas, testicular carcinomas, squamous cell 
carcinomas of the cervix, head, and neck (Lazo et al., 1996; Povirk, 1996). It is often 
used in combination therapy with other agents such as cisplatin (Einhorn, 2002; Jani et 
al., 1992; Umezawa, 1971; Wharam et al., 1973). Although bleomycin treats testicular 
carcinomas with high cure rate (~80%) (Einhorn, 2002; Hecht, 2000; Jani et al., 1992; 
Umezawa, 1971; Wharam et al., 1973), it is not effective for other types of cancer 
including colon, breast, and ovarian (Lazo et al., 1996; Povirk & Austin, 1991). 
Therefore, it is likely that a specific mechanism is involved in responding to bleomycin 
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treatment in some tumors but not in the others. While the mechanism(s) describing the 
reason for resistance of some tumors towards bleomycin treatment has not yet been 
found, the possible explanations include: (1) increased repair of bleomycin-induced 
DNA lesions, (2) decreased bleomycin uptake, (3) increased bleomycin efflux, and (4) 
inactivation or degradation of bleomycin by bleomycin-hydrolase (Akiyama et al., 
1981; Jani et al., 1992; Mir et al., 1996; Miyaki et al., 1975; Morris et al., 1992; Sanz 
et al., 2002; Sebti et al., 1991; Urade et al., 1992). 
 
1.1.2 Structure of bleomycin 
Bleomycin consists of three functional domains, the N-terminal metal-binding 
domain, the C-terminal DNA-binding domain, and the carbohydrate moiety (Fig. 1). 
The DNA binding domain contains a polyamine-like region (Abraham, 1999; Hecht, 
1986; Hoehn et al., 2001; Leitheiser et al., 2000; Petering et al., 1996). 
The N-terminal domain is essentially required for the antitumor effect of 
bleomycin. This domain interacts with molecular oxygen as well as both redox-active 
and non-redox-active metal ions such as iron and cobalt respectively (Ehrenfeld et al., 
1985; Ehrenfeld et al., 1987; Hoehn et al., 2001; Levy & Hecht, 1988; Oppenheimer et 
al., 1980; Petering et al., 1996). The metal ion has crucial role in: (1) interaction 
between bleomycin and DNA, and (2) oxygen activation resulting in generation of a 
reactive radical species (Burger et al., 1981a; Ehrenfeld et al., 1985; Ehrenfeld et al., 
1987; Oppenheimer et al., 1981; Sausville et al., 1976; Sausville et al., 1978). 
Although the C-terminal is required to bind DNA (Abraham, 1999; Hecht, 
1986), its chemical modification does not prevent DNA cleavage (Abraham, 1999).  
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Whereas the role of carbohydrate moiety is unknown, bleomycin lacking this 
domain has less effect on DNA cleavage (Leitheiser et al., 2000). 
 
 
 
 
 
 
Figure 1: Structure of bleomycin 
Bleomycin possesses three functional domains, the N-terminal metal-binding domain, 
the C-terminal DNA-binding domain, and the carbohydrate moiety (Ramotar & Wang, 
2003). 
 
 
 
 
 
1.1.3 Bleomycin-inducted DNA lesions  
Bleomycin induces DNA lesions through a free radical-driven process (Burger, 
1998). First, reduced form of iron (Fe II) binds to metal domain of bleomycin and in the 
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presence of oxygen, the bleomycin (Blm)-Fe(II)-O2 complex is formed (Burger et al., 
1979; Burger et al., 1981a). This activated complex is able to attack DNA to generate at 
least 4 types of DNA lesions. Several factors such as presence or absence of oxygen 
influence the type of DNA lesion generated by bleomycin (Burger, 1998; Suzuki et al., 
1970; Terasima & Umezawa, 1970; Tounekti et al., 2001; Umezawa et al., 1966).  
In the absence of molecular oxygen, bleomycin abstracts a hydrogen atom from 
the 4’ carbon of deoxyribose to make an unstable ring (Burger et al., 1980; Burger et al., 
1981b; Ekimoto et al., 1980; Povirk et al., 1977) (Fig. 2). The unstable sugar forms an 
oxidized (ketoaldehyde) apurinic/apyrimidinic (AP) site, where the DNA strand is 
missing a base (Burger, 1998; Worth et al., 1993).  
In the presence of oxygen, bleomycin can damage the sugar to create a single-
strand break where 3’-terminus is blocked by 3’-phosphoglycolate (3’-PG). This lesion 
blocks DNA synthesis (Burger, 1998; Giloni et al., 1981; Worth et al., 1993). 
Remarkably, the remaining portion of the fragmented sugar (base propenal), which is 
able to react with DNA to create base adducts, can interact with guanine to generate 
M1G lesion, 3-(2’-deoxy-β-D-erythro-pentofuranosyl)-pyrimido[1,2-a]purin-10(3H)-
one (Dedon et al., 1998) (Fig. 2).  
Bleomycin creates bi-stranded DNA lesions at CGCC sequences as well. This 
lesion is generated when the bleomycin makes an AP site on one strand and a single-
strand break on the complementary strand (Absalon et al., 1995b; Dedon & Goldberg, 
1992; Hoehn et al., 2001; Steighner & Povirk, 1990a). 
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Figure 2: Structure of DNA lesions 
A, in the absence of molecular oxygen, bleomycin creates an unstable ring resulting in 
formation of an oxidized apurinic/apyrimidinic (AP) site. In the presence of oxygen, 
bleomycin generates a single-strand break where 3’-terminus is blocked by 3’-
phosphoglycolate (3’-PG). B, the M1G lesion is generated by interaction between base 
propenal and guanine (Ramotar & Wang, 2003). 
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Bleomycin is also able to cleave mRNA, tRNA as well as rRNA at 5’-GU-3’ 
sequences through an oxidative pathway similar to the mechanism involved in DNA 
cleavage (Carter et al., 1990; Hecht, 1994; Holmes et al., 1993; Huttenhofer et al., 1992; 
Keck & Hecht, 1995; Morgan & Hecht, 1994). Therefore, bleomycin-induced cell death 
might result from the destruction of more than one target. However, it is unlikely that 
RNA is the main target of the bleomycin (Carter et al., 1990; Holmes & Hecht, 1993; 
Huttenhofer et al., 1992). 
 
1.1.4 Mechanisms involved in repairing the bleomycin-induced 
DNA lesions 
Since bleomycin induces formation of DNA lesion leading to cell death, cells 
exposed to this drug must activate the mechanism(s) involved in repairing the 
damaging DNA. In yeast, the mechanisms required to remove specifically bleomycin-
induced DNA lesions have not yet been well characterized. However, Apn1, Apn2 and 
Tpp1 which are known as enzymes required for the base-excision repair, have been 
demonstrated to be involved in removing the lesions induced by bleomycin (Leduc et 
al., 2003; Vance & Wilson, 2001a; Vance & Wilson, 2001b). Apn1 and Apn2 are able 
to cleave DNA at AP site as well as to remove the blocked 3’-terminus at strand breaks. 
These enzymatic activity leads to regeneration of 3’-hydroxyl group which results in 
DNA repair synthesis (Demple et al., 1986; Levin et al., 1988; Ramotar et al., 1991; 
Ramotar & Wang, 2003). Tpp1 functions only on 3’-phosphate at the single-strand 
breaks (Ramotar & Wang, 2003; Vance & Wilson, 2001a). It has been documented that 
the mutants lacking all three enzymes (apn1∆ apn2∆ tpp1∆) are extremely 
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hypersensitive to bleomycin, while single mutants are not significantly sensitive to the 
drug (Leduc et al., 2003; Vance & Wilson, 2001b). Moreover, recombination and post-
replication DNA-repair pathways are also involved in the repair of DNA lesions 
induced by bleomycin (Ramotar & Wang, 2003).  
 
1.2 Genome-wide screen  
As it was pointed out above, it is unclear how certain cancers such as colon 
carcinoma do not respond to bleomycin. Our group has performed a genome-wide 
screen with the Saccharomyces cerevisiae strains, each deleted for a single non-
essential gene in order to identify mutants that exhibit resistance or hypersensitivity to 
the drug when grown in rich media (Aouida et al., 2004b). The screens detected only 
five mutants (agp2∆, sky1∆, ptk2∆, brp1∆ and fes1∆) that were resistant to bleomycin. 
Among these mutants, agp2∆ mutant revealed the greatest resistance (Aouida et al., 
2004b). Agp2 is very well characterized as transporter of L-carnitine in the cells (Lee et 
al., 2002; van Roermund et al., 1999). Our group has demonstrated that Agp2 acts as 
transporter of both bleomycin (Aouida et al., 2004b) and polyamine (Aouida et al., 
2005). The screens also identified 231 hypersensitive mutants (4- to 20-fold more 
sensitive as compared to the parent). The corresponding genes encode the proteins that 
are involved in many biological processes including DNA repair, chromatin remodeling 
and the proper functional maintenance of the mitochondria and vacuoles (Aouida et al., 
2004b). It is noteworthy that amongst the hypersensitive mutants, the group consisting 
of the largest number of bleomycin-sensitive genes belongs to the endosomal pathway 
(Aouida et al., 2004b). Deletion of any one of these genes resulted in varying 
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sensitivity to bleomycin implying that this pathway plays a crucial role in preventing 
the toxicity of the drug (Aouida et al., 2004a; Aouida et al., 2004b). 
 
1.3 Endocytic pathway 
Endocytosis is a trafficking mechanism involved in internalization of the 
extracellular and plasma membrane components which either are recycled to the plasma 
membrane or delivered to the vacuole (Henkel et al., 1999; Samaj et al., 2004; Shaw et 
al., 2001). The yeast vacuole, equivalent to lysosome in higher eukaryotes, is an 
organelle involved in degradation of cytoplasmic proteins (Chiang & Schekman, 1991). 
Endocytosis has been detected in all the eukaryotic cells (Geli & Riezman, 1998). It has 
been documented that some processes such as actin regulation, ubiquitylation, lipid 
modification, and signal transduction are involved in the endocytic pathway (Shaw et 
al., 2001). Remarkably, several screens have identified the mutants such as vacuolar 
protein sorting (vps) and vacuolar abnormal morphology (vam) which are defective in 
protein trafficking to the vacuole. The vacuolar protein sorting (vps) mutants are 
divided to six classes (A-F) depending on the phenotype (Banta et al., 1988; Bowers & 
Stevens, 2005; Raymond et al., 1992). The mutants in the same class are often 
defective in the same step of protein trafficking.  
Two types of endocytosis have been characterized based on cargo: fluid 
endocyosis and receptor-mediated endocytosis. In the fluid endocytosis, cargos consist 
of the bulk solutes which do not bind to the membrane. They are engulfed in a vesicle 
that is subsequently delivered into the cell (Ferris et al., 1987; Swanson et al., 1985). In 
the receptor-mediated endocytosis, internalization requires specific proteins on the cell 
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surface which function as receptor to bind their ligands (macromolecular cargos) 
(Lamaze & Schmid, 1995; Penalver et al., 1997). In contrast to receptor-mediated 
endocytosis, fluid endocyosis is not saturable with respect to the external concentration 
(Riezman, 1985; Swanson et al., 1985). Fluid endocyosis and receptor-mediated 
endocytosis share some features. 
Since the receptors involved in endocytosis of bleomycin and the other drugs 
used in this study are not yet known, α-factor endocytosis is explained to provide a 
general description of the receptor-mediated endocytosis. The receptor-mediated 
endocytosis for bleomycin remains to be detected.  
Initially, the specific plasma membrane proteins, eisosomes, act as organizing 
sites (Walther et al., 2006). Clathrin, a multimeric protein, is consequently recruited 
(Newpher et al., 2005). Clathrin is required for recruitment of the later proteins, but 
does not play significant roles in yeast endocytosis (Kaksonen et al., 2005). In fact, it 
has been documented that the clathrin-deficient cells resulted from deletion of CHC1 
gene retain the ability to deliver the cargos to the vacuole (Payne et al., 1988). α-factor 
which is a small peptide secreted by MATα cells binds to its receptor, Ste2, at the 
endocytic site of the MATa cells (Baggett & Wendland, 2001). Ste2 belongs to a group 
of transporters that possess 7-transmembrane segments (7-TMS) with trimeric G-
proteins-dependent function (Singer & Riezman, 1990; Tan et al., 1993). Ligand-
receptor binding leads to Ste2 modification such as phosphorylation and ubiquitylation 
which act as signals for internalization (Engqvist-Goldstein & Drubin, 2003; Hicke et 
al., 1998; Howard et al., 2002). The recruitment of a subset of proteins involved in 
actin assembly such as Arp2/3 and class I myosin result in initiation of the actin 
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assembly. While, mutations in many genes which encode the proteins such as 
tropomyosin and myosins V cause significant defects in the actin cytoskeleton, 
endocytosis is not affected in these mutants (Riezman et al., 1996). Therefore, it is 
likely that the proteins involved in actin assembly are very specific. The assembling 
actin and myosin activity lead to plasma membrane inward (Sun et al., 2006). The 
internalization is followed by releasing of the vesicle and consequently coat and actin 
disassembly. The coat components is recycled in order to generate more vesicle 
(Toshima et al., 2005). The endocytic vesicles connection with actin cable lead to 
efficient association of the vesicle to the early endosome (Huckaba et al., 2004; 
Toshima et al., 2006).  
The internalized proteins have two distinct destinations, either they are returned 
to the plasma membrane or delivered to the vacuole for degradation. The first step of 
the sorting occurs at the early endosome where the proteins for recycling to the plasma 
membrane are transported to the trans-Golgi network (TGN). These proteins are 
consequently returned to the cell surface through the exocytic secretory pathway. The 
proteins which are not recycled enter the late endosome/prevacuolar compartment 
(Shaw et al., 2001). It is noteworthy that some proteins could be either recycled to the 
plasma membrane or delivered to the vacuole. While, the Ste3 known as a-factor 
receptor is recycled in a ligand dependent manner, it is targeted to vacuole in absence 
of a-factor (Shaw et al., 2001). Progressive maturation of the early endosome leads to 
generation of the late endosome (Russell et al., 2006). 
The invagination of vesicles from the membrane of the late 
endosome/prevacuolar compartment into the endosomal lumen generates a 
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multivesicular body (MVB). The proteins which will be degraded in the vacuole (e.g., 
endocytic cargo) or the proteins which need to undergo special processing in the 
vacuole (e.g., pCPY) are sorted into these vesicles. It has been demonstrated that MVB 
sorting requires ubiquitylation of the cargo. Ubiquitin acts as recognition signal for 
entry of the cargo to MVB (Katzmann et al., 2001; Shaw et al., 2001). Four endosomal 
sorting complexes required for transport (ESCRT) are involved in transport of the cargo 
to MVB vesicle in Saccharomyces cerevisiae. These complexes (ESCRT-0, ESCRT-I, 
ESCRT-II and ESCRT-III) comprise the soluble “class E” vacuolar sorting proteins 
(Vps) which selectively bind the cargos and direct sorting of these cargos to MVB 
vesicles (Bowers & Stevens, 2005). 
Protein sorting initiates via generating Phosphatidyl inositol 3-phosphate (PI3P) 
at the late endosome membrane where ESCRT-0 recruitment results in ubiquitylation of 
the non-ubiquitylated cargos by Rsp5. ESCRT-I is consequently recruited to form a 
complex with ESCRT-0 and ubiquitylated cargos. ESCRT-I functions to recruit 
ESCRT-II and ESCRT-III. While, ubiquitylated cargos bind to ESCRT-I and ESCRT-II, 
ESCRT-III interacts with lipids and ESCRT-III-associated proteins. Cargos 
deubiquitylation requires deubiquitylating enzyme Doa4 which is known as crucial 
protein in removing ubiquitin from ubiquitylated cargos. A protein which belongs to 
ESCRT-III-associated proteins is involved in Doa4 recruitment. ESCRT-III-associated 
proteins and the ESCRT complexes dissociate from the membrane and cargos are 
sorted to invaginating MVB vesicle (Fig. 3) (Bowers & Stevens, 2005; Zhang et al., 
2008). The cargos such as Ste2, which are previously ubiquitylated for internalization, 
use the same ubiquitin modification during MVB sorting. Furthermore, the endocytosed 
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proteins could be deubiquitylated after internalization and the reubiquitylated for MVB 
sorting (Shaw et al., 2001). 
Remarkably, the proteins destined to remain intact in the vacuolar membrane, 
without undergoing degradation, are not sorted from the late endosome into the 
multivesicular body. These proteins are directly incorporated into the limiting vacuolar 
membrane (Shaw et al., 2001). 
The multivesicular body eventually fuses with the vacuole and releases its 
intralumenal vesicles into the vacuole where the cargos are degraded or undergo special 
processing (Odorizzi et al., 1998; Shaw et al., 2001). Fusion with the vacuole requires 
homotypic fusion and protein sorting complex (HOPS), Rab GTPase Ypt7 as well as 
SNARE complex (Bowers & Stevens, 2005). The HOPS complex consists of several 
proteins in “class C” of vacuolar protein sorting (Vps). This complex is involved in 
activation of Ypt7 and acts as Ypt7 effector. The activated Ypt7 is believed to tether 
vacuole and late endosome membrane compartment. The tethering leads to membrane 
fusion via the integral membrane proteins (SNARE) (Bowers & Stevens, 2005; 
Wurmser et al., 2000). 
Vacuolar delivery of the cargos could be affected in the mutants defective in the 
“class E” of vacuolar protein sorting (Vps). In these mutants, late endosome is unable 
to mature into the multivesicular body resulting in accumulation of the cargos in an 
aberrant and enlarged late endosome (Katzmann et al., 2001; Odorizzi et al., 1998; 
Shaw et al., 2001). 
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Figure 3: Model for protein sorting into the MVB vesicles 
ESCRT-0 is required for cargo ubiquitylation. Ubiquitylated cargo is recognized by 
ESCRT-I, which initiates cargo entry into MVB vesicles. Function of some additional 
class E Vps proteins result in recruitment of the deubiquitylating enzyme Doa4 to 
remove ubiquitin from cargo prior to its entry into invaginating vesicles (Bowers & 
Stevens, 2005). 
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1.4 Nhx1 
The Na+/H+ antiporters (NHE proteins) are required for the exchange of Na+ for 
H+ across membranes and play a role in regulation of internal pH, cell volume, and 
sodium level in the cytoplasm (Wells & Rao, 2001). In Escherichia coli, three 
antiporters (NhaA, NhaB, and ChaA) (Ohyama et al., 1994); in mammals, nine 
members of Na+/H+ antiporters (exchangers) (NHE1-9) (Mukherjee et al., 2006); in 
Saccharomyces cerevisiae, two plasma membrane transporters (Nha1& Ena1-4) 
(Kinclova-Zimmermannova et al., 2006) and one intracellular transporters (Nhx1) 
(Nass et al., 1997; Nass & Rao, 1998); in plants, Na+/H+ antiporters isolated from some 
species such as Arabidopsis thaliana (AtNhx1) (Gaxiola et al., 1999) have been 
reported.  
In yeast, the NHX1 gene which has been identified as VPS44 (Bowers et al., 
2000) encodes an intracellular Na+/H+ exchanger, which is located in the late 
endosomes/prevacuolar compartment (Nass & Rao, 1998). It is involved in regulating 
vesicle trafficking out of the prevacuolar compartment to the vacuoles (Bowers et al., 
2000). Nhx1 is also required to mediate vacuolar sequestration of Na+ and K+ by 
coupling their transport to the H+ gradient created by the vacuolar H+-ATPase (Nass et 
al., 1997). Thus, mutant lacking Nhx1 is reported to be sensitive to NaCl in media with 
low ionic strength (Brett et al., 2005; Wells & Rao, 2001). It has been shown that the 
role of Nhx1 in cellular physiology is not limited to ion homeostasis, as nhx1∆ mutant 
reveal a phenotype of the “class E” vacuolar protein sorting (vps) mutants resulting in 
enlargement of the late endosomal or prevacuolar compartment (Bowers et al., 2000). 
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Nhx1 contains 12 transmembrane segments, as well as a C-terminal hydrophilic 
domain that is involved in protein–protein interactions (Fig. 4) (Mukherjee et al., 2006). 
The C-terminal tail of Nhx1 was shown to interact with C-terminal region of Gyp6, a 
GTPase-activating protein involved in Ypt6-mediated retrograde traffic to the Golgi 
(Ali et al., 2004). Evidence suggests that Gyp6 negatively regulates Nhx1 function and 
that Nhx1 may exert a role to allow trafficking from the prevacuole to the late Golgi via 
Ypt6 (Ali et al., 2004).  
 
 
            
 
Figure 4: Topology model of Nhx1 
Nhx1 consists of 12 transmembrane domains with C-terminal and N-terminal tails 
located in cytoplasmic side (Ali et al., 2004). 
 
 
 
 
To date, the phenotypes reported for nhx1∆ mutant include sensitivity to NaCl 
(Brett et al., 2005; Wells & Rao, 2001) hygromycin B (Ali et al., 2004; Brett et al., 
2005), bleomycin (Aouida et al., 2004b) and gentamicin, an aminoglycoside antibiotic 
used for killing Gram-negative bacteria (Wagner et al., 2006). In addition, nhx1∆ 
mutant displayed missorting of carboxypeptidase Y (CPY) causing its secretion into the 
growth media (Ali et al., 2004).  
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1.5 CPY secretion 
 In Saccharomyces cerevisiae, PRC1 encodes carboxypeptidase Y (CPY) (Ohi et 
al., 1996) which is required for the proteolytic function of the vacuole (Van Den Hazel 
et al., 1996). It has been recently demonstrated that CPY is also required in the 
synthesis of phytochelatins (Wunschmann et al., 2007). In eukaryotes, the 
phytochelatins consist of the cysteine-rich peptides with low molecular weight which 
sequester excess heavy metal ions and maintain metal ions homeostasis (Cobbett & 
Goldsbrough, 2002; Rea et al., 2004; Zenk, 1996). 
  CPY is synthesized as an initial precursor (preproCPY) contains a 20 amino 
acid signal peptide in N-terminal which is followed by a 91 amino acid propeptide. The 
initial precursor then enters the lumen of the endoplasmic reticulum where removal of 
signal peptide resulting in formation of the inactive precursor (proCPY). The inactive 
precursor rapidly becomes N-glycosylated and is transported to the Golgi where the 
elongation of the carbohydrate side chains results in the 69 KDa proCPY. The proCPY 
is channeled to the late Golgi by its receptor. Vps10p, the CPY receptor, binds proCPY 
in the late Golgi and moves to the late endosome where proCPY is released. Vps10p is 
then returned to the late Golgi to capture and carry more proCPY (Fig. 5) (Bowers et 
al., 2000; Cereghino et al., 1995; Cooper & Stevens, 1996; Marcusson et al., 1994). 
The vacuole is the final destination for proCPY. Cleavage of the propeptide by 
proteinase B (Prb1p) leads to formation of  the active 61 kDa CPY, which is the last 
step in the maturation of CPY (Sorensen et al., 1994).  
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Figure 5: Vps10 is involved in trafficking of CPY 
Vps10 acts as transporter to carry CPY to the late endosome (LE) where CPY is 
released from Vps10. Then, CPY is transported to the vacuole to form mature CPY 
(mCPY). Vps10 is recycled back to the Golgi (Bowers & Stevens, 2005). 
 
 
 
 
Propeptide acts as a chaperone to ensure the proper folding of the CPY during 
its maturation. It also inhibits the hydrolytic activity until the protein reaches its final 
destination (Winther & Sorensen, 1991). It is noteworthy that Tfs1 has been 
characterized as high-affinity inhibitor of yeast CPY (Bruun et al., 1998). 
There are also two other pathways for the newly synthesized proteins which are 
destined for the vacuole. (i) The vacuolar proteins such as alkaline phosphatase (ALP) 
enter the vacuole directly from late Golgi, by-passing late endosome (Bowers et al., 
2000; Cowles et al., 1997; Piper et al., 1997), and (ii) The proteins which have been 
carried to the cell surface enter the vacuole through endocytosis (Fig. 6) (Bowers et al., 
2000). 
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Figure 6: Protein trafficking pathways to the vacuole in yeast 
The newly synthesized proteins are secreted or transported to early endosomes (EE). 
The proteins can also be taken to the vacuole via the late endosome/multivesicular body 
(MVB) (the CPY pathway). The ALP pathway sorts proteins to the vacuole from the 
late Golgi via an alternative route, bypassing the endosomal network (Bowers & 
Stevens, 2005). 
 
 
Since the endocytosis pathway converge with CPY route at the late endosome 
(Davis et al., 1993; Piper et al., 1995; Rieder et al., 1996), CPY is extensively used to 
monitor the proteins transport pathway to the vacuole as well as the function of  the 
endosome and the vacuole (Bryant & Stevens, 1998; Gabriely et al., 2007; Losev et al., 
2006). For example, the vacuolar protein sorting (vps) mutants including the “class E” 
vps mutants secrete abnormally CPY and other vacuolar hydrolases into the 
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extracellular medium (Raymond et al., 1992; Rothman & Stevens, 1986). In “class E” 
vps mutants cells, Vps10p accumulates in the large and aberrant late endosome and is 
not able to recycle to the late Golgi to transport more CPY (Cereghino et al., 1995; 
Piper et al., 1995; Rieder et al., 1996). This defect is the main reason of CPY secretion 
in the “class E” compartment. The collected CPY in the late Golgi is then secreted into 
the extracellular medium. Vps10p accumulated in the late endosome cleaves to a 
smaller form (Vps10p*) via an abnormal proteolytic cleavage (Bowers et al., 2000; 
Cereghino et al., 1995; Piper et al., 1995). Since ALP directly enters the vacuole via the 
Golgi, by-passing the late endosome, transport through the ALP pathway is not affected 
in “class E” vps mutants (Bowers et al., 2000). 
The last step in CPY and ALP pathways is the fusion of the late endosome with 
the vacuole. This step is controlled by a complex of the proteins including Vam3p, 
Vti1p, Vps43p/Vam7p, Ykt6p, Rab GTPase Ypt7p as well as a complex of “class C” 
vacuolar protein sorting (Vps) (Kweon et al., 2003; Mayer et al., 1996). 
 
1.6 Rationale 
 
  As genome-wide screen revealed that the mutants defective in endocytic 
pathway show hypersensitivity to bleomycin, we decided to conduct additional 
characterization of one of the endosomal pathway genes, namely NHX1, as deletion of 
this gene resulted in mutant with severe sensitivity to bleomycin (unpublished data). It 
has been shown that nhx1∆ mutant is sensitive to NaCl and hygromycin B but these 
sensitivities were reported under conditions of a special growth media (APG) 
containing low salt where the investigators suggested that these phenotypes could be 
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correlated with a defect in the mutant ability to maintain salt and pH homeostasis (Brett 
et al., 2005). In contrast, the sensitivity to bleomycin and gentamicin were observed 
with rich growth media (Aouida et al., 2004b; Wagner et al., 2006). These combined 
studies raised the possibility that nhx1∆ mutant phenotypes may depend upon the 
growth media. In this study, we examined the nhx1∆ mutant for sensitivity to cationic 
and anionic drugs that enter the cell via both receptor mediated and fluid endocytosis, 
as well as to various DNA damaging agents with different mode of action, when the 
cells were cultured only in rich growth media. We showed that nhx1∆ mutant is 
sensitive to several of these agents, but the sensitivity was not influence either by pH or 
NaCl. We further showed that nhx1∆ mutant secretes CPY, but which was also not 
prevented by changes in pH or NaCl concentrations. We concluded that Nhx1 plays a 
general role to detoxify those drugs that are channeled to the vacuole via the endosomal 
pathway, and that on its absence there is likely a leak from the prevacuole into the 
cytosol resulting in the observed toxicity.  
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Chapter 2 Materials and methods 
2.1 Yeast strains, media and plasmid 
The S. cerevisiae strains used in this study are listed in Table 1. Cells were 
grown at 30ºC in either yeast peptone dextrose (YPD) (1% (w/v) yeast extract, 2% (w/v) 
peptone, 2% (w/v) dextrose) or minimal synthetic (SD: 0.65% yeast nitrogen base 
without amino acids, 2% dextrose, 0.17% dropout mix) used for transformation 
(Guthrie & Fink, 1991). pRin73, a 2µ plasmid harbouring NHX1 tagged with a C-
terminal triple hemagglutinin epitope (NHX1-HA), under control of its endogenous 
promoter, was kindly provided by Dr. Rajini Rao (Johns Hopkins, USA).  
 
Table 1: Strains 
Strain                                                   Genotype 
 
BY4741 (parent) MATa his3∆ leu2∆ met15∆ ura3∆ 
BY4741 (nhx1∆)  Isogenic to BY4741, except nhx1::KAN 
BY4741 (agp2∆) Isogenic to BY4741, except agp2::URA3  
BY4741 (vma12∆) Isogenic to BY4741, except vma12::KAN 
BY4741 (vps27∆) Isogenic to BY4741, except vps27::KAN 
BY4741 (ypt6∆)  Isogenic to BY4741, except ypt6::KAN 
BY4741 (ypt7∆)  Isogenic to BY4741, except ypt7::KAN 
BY4741 (nhx1∆ ypt6∆) Isogenic to BY4741, except nhx1::KAN 
ypt6::LEU2 
W303 (parent) MATa ade2∆ leu2∆ trp1∆ ura3∆ his3∆ 
 
 
2.2 Plasmid amplification in E.coli 
E.coli incubation for 30 minutes on ice was followed by a heat chock at 42ºC 
for a precise time (90 seconds). The sample was incubated at 37ºC for 1 h after adding 
1 ml LB media (0.5% (w/v) yeast extract, 1% (w/v) tryptone, and 1% (w/v) NaCl). 
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Finally, cells were spun down (10,000 rpm, 2 minutes), resuspanded in 100 µl LB 
media and plated in LB-Agar 1.5% containing 100 µg/ml Ampicilin. The plates were 
incubated at 37ºC overnight.  
 
2.3 Plasmid purification from E.coli 
One colony grown on LB media was inoculated in 5 ml LB containing 100 
µg/ml Ampicilin and incubated at 37ºC over night. The next day, the sample was spun 
down (12,000 rpm, 5 minutes) and 100 µl of solution I (50 mM glucose, 25 mM Tris-
HCl pH 8, 10 mM EDTA pH 8) were added to the supernatant. After homogenization, 
200 µl of solution II (0.2 M NaOH, 1% SDS) were added and the contents thoroughly 
were mixed by gently inverting the tube several times. Five minutes incubation at room 
temperature was followed by adding 150 µl solution III (5 M potassium acetate, 11.5% 
glacial acetic acid). After ice incubation for 10 minutes, the sample was spun down 
(10,000 rpm, 5 minutes). The next step is to add 500 µl phenol and 500 µl chloroform 
to the supernatant. After centrifugation, the sample which consisted of the supernatant 
and 1 ml of 100% ethanol was kept at -20ºC for 10 minutes and then was spun down for 
10 minutes at high speed (14,000 rpm). The supernatant was decanted and the pellet 
was rinsed by 500 µl of 70% ethanol. The ethanol was drained off and the pellet was 
dissolved in 50 µl TE (10 mM Tris-HCl pH 8, 1 mM EDTA pH 8).  
 
2.4 Transformation 
Wild-type and nhx1∆ mutant were grown in 2 ml YPD media overnight and 
subcultured in fresh YPD at 30ºC for 4 h. Cells were washed twice with 5 ml of 
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sterilized water and spun down for 5 minutes at 1,000 rpm. The pellet was washed in 
800 µl of TE/LiAc (10 mM Tris-HCl, 1 mM EDTA, 100 mM LiAc pH 7.5) and 
resuspended in 50 µl of TE/LiAc. The following samples (table 2) were then prepared 
and incubated at 30ºC for 45 minutes. 
 
Table 2: Transformation Protocol 
                                             BY4741                             BY4741 (nhx1∆) 
Sample  1 2           3                      4          5            6 
Cell                             50 µl    50 µl      50 µl                50 µl     50 µl      50 µl 
Carrier DNA             5µl        5 µl        5 µl                  5µl        5 µl        5 µl 
Plasmid                      -           5 µl       -                      -           5 µl         - 
Vector YCplac111    -              -          5 µl                  -             -           5 µl 
PEG solution*           300 µl 300 µl     300 µl            300 µl    300 µl     300 µl 
 
* PEG solution: TE/LiAc 1 X and 40% PEG (polyethylene glycol). 
Cells were then incubated at 42ºC for 15 minutes. The pellet was collected by 
centrifugation for 2 minutes at 10,000 rpm and resuspended in 100 µl of sterilized water 
and plated on selective media plates. The plates were incubated at 30ºC for 2 days. The 
single colonies from plates of samples 2, 3, 5 and 6 were purified by patching on the 
new selective media. 
 
2.5 Spot tests  
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Cells were grown overnight at 30ºC in 2 ml YPD media and were subcultured in 
3 ml fresh YPD media for 4 h. Exponentially growing cells were diluted to an A600 of 
0.6. Cell suspensions were then serially diluted as indicated and 5 µl were spotted onto 
YPD agar containing described amount of the drugs. Plates were photographed after 48 
h of incubation at 30°C. 
 
2.6 Spermidine uptake analysis 
Prior to the polyamine uptake assay, cells were grown to the mid logarithmic 
phase, washed three times with uptake buffer A ( 50 mM sodium citrate, pH 5.5, 2% D-
glucose), and resuspended in 100 µl of the same buffer at 2 X 107 cells/ml. The uptake 
assay was initiated by the addition of 2.5 µM [14C] spermidine followed by incubation 
at 30ºC with shaking. The reaction was stopped at predetermined intervals by adding 1 
ml of ice-cold uptake buffer. Cells were washed three times with uptake buffer and 
resuspended in 100 µl of the this buffer. Five ml of scintillation mixture (Amersham 
Bioscience) were added to each sample, and the retained radioactivity was determined 
by liquid scintillation spectrometry. 
 
2.7 Western blot  
Immunoblot analysis was performed as previously described (Vongsamphanh et 
al., 2001). Briefly, yeast cells were grown overnight in selective media, washed twice 
with sterilized water and centrifuged at 4ºC at 4000rpm. The pellet was resuspended in 
yeast extraction buffer (50 mM Tris pH 7.0, 30 mM KCl, 10% glycerol, 1 µg/ml 
leupeptin, 1µg/ml aprotinin, 1 mM PMSF and 1 mM DTT) followed by homogenizing 
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via a MINI bead beater for 20 seconds at 5000rpm. Cells were beat for 6 rounds with 1 
minute intervals on ice. Protein was collected after removal of cellular debris via 
centrifugation at 9000 g for 10 minutes. A Bradford assay was used for protein 
quantification. 150 µg of whole cell lysate per lane was loaded onto 10% SDS-PAGE 
gel. The gel was run for approximately 1 h at 120 V/ 20 mA until the dye reached close 
to the end of the gel. The running buffer condition was as follows: 25 mM Tris pH 7.0, 
192 mM Glycine and 0.1% SDS. The proteins were then transferred to a nitrocellulose 
membrane at 100V/250 mA for 1 h. Transfer buffer condition: 25 mM Tris pH 7.0, 192 
mM Glycine, 0.05% SDS and 20% methanol. The blot was blocked with a blocking 
buffer (10 mM Tris, 0.15 M NaCl, 1.26 mM EDTA, 0.001% Tween 20 and 5% nonfat 
dried milk). The blot was then incubated with anti-HA monoclonal antibody (Santa 
Cruz Biotechnology) at a dilution of 1:5000, and the secondary antibodies were anti-
mouse (Amersham Bioscience). Protein bands were revealed by using PerkinElmer 
Chemiluminescne Reagent Plus followed by exposure to Kodak double emulsion film. 
 
2.8 Coomassie staining 
Samples were resolved by SDS-PAGE gels. SDS–polyacrylamide gels were 
stained with coomassie for 30 min in 4.6% methanol (v/v), 9.2% acetic acid, and 0.25% 
(w/v) coomassie Brilliant Blue R-25 and then destained in 7.5% acetic acid and 12% 
methanol. 
 
2.9 CPY plate assay  
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Exponentially growing cells OD600 ~0.6 were serially diluted. Five µl aliquots 
were spotted on a nitrocellulose membrane (Amersham Biosciences) which was placed 
on the surface of YPD or SC plates and incubated at 30ºC for 12-18 h. The membrane 
was lifted and washed with deionized and distilled water to remove all cells. Proteins 
absorbed on the membrane were detected by immunoblotting using monoclonal CPY 
antibody (molecular Probes; 1:2500 dilution). The data represent results from three 
independent experiments. 
 
2.10 Quinacrine vacuole staining 
Vacuolar accumulation of quinacrine was examined as described previously 
(Roberts et al., 1991). Briefly, 3 X 107 log-phase yeast cells were harvested and 
resuspended in 500 µl of YPD buffered with 50 mM Na2HPO4, pH 7.6, and containing 
200 mM quinacrine. After incubation at the room temperature for 5 min, cells were 
sedimented at 10,000 g for 5 s, washed once with 500 µl of 2% glucose buffered with 
50 mM Na2HPO4, pH 7.6, and resuspended in 100 µl of the same solution. Samples 
were applied to a microscope slide and photographed by a fluorescent microscope. 
 
2.11 UVC treatment 
Overnight cultures were sub-cultured into 4 ml YPD and cells at O.D600 ~1.0 
were harvested and resuspended in 4 ml of 20 mM PBS buffer. The cells were diluted 
10-4 and 100 µl plated on YPD agar. Plates were irradiated with 254nm UVC (0-90 
J/cm2) and scored for survival after 2 days of growth at 30°C. 
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2.12 RT-PCR 
2.12.1 RNA extraction  
Total RNA was prepared using the RiboPure-Yeast extraction kit (Ambion). 
Briefly, 3 ml overnight cultures were spun down and the pellet was resuspended in lysis 
reagents consisting of lysis buffer, 10% SDS and phenol:Chloroform:IAA. The mixture 
of the cells were transferred to the tubes containing 750 µl cold Zirconia Beads. Cells 
were beat on the vortex adapter for 10 minutes at maximum speed. After centrifugation 
at 16,000 X g at room temperature, the aqueous phase of each sample was transferred to 
the new tube. 1.9 ml binding buffer and 1.25 ml of 100% ethanol were then added to 
each sample. The samples were drawn through a filter cartridge. The filters were 
washed with wash solutions 1 and 2/3 and RNA was eluted by applying RNA elution 
buffer. Isolated RNA contains chromosomal DNA. To remove it, DNase digestion 
reaction at room temperature was assembled: 50-100 µl RNA sample, 1/10th volume of 
10X DNase 1 buffer and 4 µl DNase 1 (8U). The sample was incubated 30 minutes at 
37°C. Total RNA was quantified by absorption at 260 nm. 
 
2.12.2 cDNA Synthesis 
 To synthesize cDNA, the following components were added to a nuclease-free 
tube: 5 µg RNA, 1 µl of 10 mM dNTP, 250 ng random primers (Invitrogen) and sterile 
water to total volume of 12 µl. The mixture was heated to 65°C for 5 minutes. Then, 4 
µl of 5 X first-strand buffer, 2 µl of 0.1 M DTT and 1 µl RNaseOUTTM were added and 
the sample was incubated at 37°C for 2 minutes. One µl of M-MLV RT (Reverse 
transcriptase) (200 units) was gently mixed with the sample and the following 
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incubations were done: 10 minutes at 25°C, 50 minutes at 37°C and 15 minutes at 70°C. 
The cDNA can now be used as template for amplification in PCR.  
 
 2.12.3 PCR Amplification 
To detect NHX1 and ACT1 expression the following PCR primers were chosen 
(Table 3). 
Table 3: PCR Primers  
 
     
                Name                                                  Sequence  
  
 
 
RT-PCR-NHX1-F1    (5'-GTTATTGGCTTGATAATAAGGATGTCCCCCGGGCA-3')           
RT-PCR-NHX1-R1    (5'-CAATTTGAGGATAGCGCCTTATGTGAGTGTGTTTCA 
ACAG-3') 
RT-PCR-ACT1-F1     (5'- GTTTTGCCGGTGACGACGCTCCTCGTGCTG-3') 
RT-PCR-ACT1-R1 (5'-CGGCTTGGATGGAAACGTAGAAGGCTGGAACG-3') 
 
PCR machine: PTC-100TM Programmable Thermal Controller MJ research INC. 
Master Mixture: 2 µl of cDNA, 2.5 µl of 10 X taq buffer, 1 µl of upstream primer 
(1µg/µl), 1 µl of downstream primer (1µg/µl), 1 µl of 10 mM dNTP, 1.5 µl of 25 mM 
MgCl2, 0.5 µl of Taq DNA polymerase (5U/µl) and add sterilized water up to 25µl. 
PCR designed program: 
1- 95ºC for 2 minutes, 2- 94ºC for 1 minute, 3- 55ºC for 1 minute, 4- 72ºC for 4 
minutes, 5- 22 times repeat of step 2-4, 6- 72ºC for 7 minutes, and 7- 4ºC. 
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Chapter 3 Results 
3.1 Deletion of the NHX1 gene confers hypersensitivity to bleomycin-
A5. 
Genome-wide screen revealed that nhx1∆ mutant is sensitive to bleomycin-A5 
(Aouida et al., 2004b). We confirmed the sensitivity of nhx1∆ mutant to this drug by 
using an independent approach. Spot test analysis revealed that the mutant was 
extremely sensitive to bleomycin-A5, when compared to the parent or agp2∆ mutant 
(Fig. 7). Since Agp2 has been demonstrated as bleomycin-A5 transporter, the cells 
show resistance to the drug when AGP2 gene is deleted (Aouida et al., 2004b). 
Therefore, in this experiment we used agp2∆ mutant as control for the spot test analysis.  
Furthermore, deletion of the NHX1 gene in another wild-type strain W303 also 
resulted in nhx1∆ mutant displaying hypersensitivity to bleomycin-A5 (data not shown). 
The nhx1/NHX1 diploid retained parental resistance to bleomycin-A5, suggesting that 
the nhx1 allele is recessive.  
We next examined whether enhanced expression of NHX1 would restore 
bleomycin-A5 resistance to the nhx1∆ mutant. A multicopy plasmid (pNHX1-HA) was 
used to overproduce Nhx1p as a HA fusion protein (Nhx1-HA) under the control of its 
own promoter. Since latter plasmid has been tagged with the triple HA, Nhx1-HA3 is 
the fusion protein used in our study but for simplicity it has been called Nhx1-HA. The 
expression of the NHX1 gene in the following six strains (i) the parent, (ii) the parent 
carrying the empty vector, (iii) the parent carrying the plasmid pNHX1-HA, (iv) the 
nhx1∆ mutant, (v) the nhx1∆ mutant carrying the empty vector, and (vi) the nhx1∆ 
mutant carrying the plasmid pNHX1-HA were assessed by performing RT-PCR. The 
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results indicated that NHX1 gene can be overexpressed in parent and mutant strains 
carrying the plasmid pNHX1-HA (Fig. 8A). Western blot analysis revealed that a total 
cell extract prepared from the nhx1∆ mutant strain carrying the plasmid pNHX1-HA 
expressed the expected 73.5 kDa fusion protein (Fig. 8B). The overexpressed Nhx1-HA 
conferred nearly full resistance to the nhx1∆ mutant towards bleomycin-A5 at the lower 
drug concentration, while at a 2-fold higher concentration (0.5 µg/ml) only partial 
resistance was observed (Fig. 7). These findings demonstrated that the NHX1 gene 
product is required to protect cells against the toxicity caused by bleomycin-A5. We 
noted that the overexpression of Nhx1-HA showed no additional bleomycin-A5 
resistance to the parent strain (Fig. 7), suggesting that Nhx1 function is not limiting in 
the cells.  
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Figure 7: Effect of the NHX1 gene deletion and Nhx1-HA expression on sensitivity 
of the indicated strains towards bleomycin. 
Exponentially growing cells were diluted to an A600 of 0.6. Cell suspensions were then 
serially diluted as indicated and 5 µl were spotted onto YPD solid media without and 
with indicated concentration of BLM (0.25 µg/ml and 0.5 µg/ml). Plates were 
photographed after 48 h of incubation at 30°C. agp2∆ mutant displayed resistance to 
the drug as previously described. The data is representative of two independent 
analyses. 
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Figure 8: Expression of NHX1 gene and Nhx1-HA fusion protein in the parent and 
nhx1∆ mutant.  
A, RT-PCR analysis to detect NHX1 and ACT1 expression in the indicated strains. B, 
Expression of Nhx1-HA fusion by Western blot analysis. Total extracts (150 µg) were 
subjected to Western blot analysis and probed with anti-HA monoclonal antibodies. C, 
Coomassie staining to monitor protein loading. 
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3.2 nhx1∆ mutant is hypersensitive to polyamines  
Since bleomycin possesses a chemical composition similar to polyamine 
structure (Aouida et al., 2004a), it is likely that bleomycin could act as anticancer 
polyamine analogue. We speculated that nhx1∆ mutant sensitivity to bleomycin might 
be a result of this specific structure. Therefore, we tested if the nhx1∆ mutant would 
display cross-sensitivity to polyamines. Although polyamines such as spermine (SPM) 
and spermidine (SPD) play multiple functions including the regulation of cell 
proliferation and cell differentiation (Heby, 1981; Stabellini et al., 1995; Stabellini et 
al., 1997), an excess of polyamines is toxic for the cells. 
Spot test analysis revealed that the nhx1∆ mutant was hypersensitive to both 
SPM and SPD. These phenotypes were rescued by the introduction of the plasmid 
pNHX1 (Fig. 9). Thus, it appears that Nhx1 function is also required to prevent 
toxicities caused by polyamines. Polyamine sensitivity can be explained by an increase 
accumulation in some mutants such as end3∆ mutant. While End3 is required for initial 
phase of endocytosis, internalization of plasma membrane proteins, mutant lacking 
End3 showed increased uptake of polyamine (Aouida et al., 2005). Our group 
demonstrated that this phenotype is due to enhanced abundance of Agp2, transporter of 
polyamine, at the plasma membrane of end3∆ mutant (Aouida et al., 2005). 
Polyamine hypersensitivity could be result of an increase accumulation in 
nhx1∆ mutant. Alternatively, NHX1 deletion could result in polyamine accumulation in 
the cells due to polyamine transporter activation as shown in end3∆ mutant. To detect 
the intracellular amount of radiolabeled polyamine, we monitored the uptake of 14C-
labeled spermidine in the nhx1∆ mutant. In comparison to the parent, the nhx1∆ mutant 
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showed only a modest increase in the accumulation of the labelled SPD (Fig. 10). 
These data exclude the possibility that the sensitivity of the nhx1∆ mutant is due to 
enhanced polyamine uptake.  
 
 
 
 
 
 
 
Figure 9: nhx1∆ mutant displays sensitivity towards polyamines 
Cells were spotted on YPD plates without and with the indicated concentration of SPM 
and SPD and photographed as in Fig. 7 after 48 h of incubation at 30ºC.  The data is 
representative of three independent analyses. 
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Figure 10. [14C] spermidine uptake in nhx1∆ mutant.  
Exponentially growing cells were incubated with [14C] spermidine and processed for 
the uptake as described in “Materials and methods”. The data represent results from 
three independent experiments. 
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3.3 Hypersensitivity of nhx1∆ mutant is not limited to bleomycin-A5 
or polyamines.  
Previous studies documented that nhx1∆ mutant show sensitivity towards 
hygromycin B (Gaxiola et al., 1999). Hygromycin B is a cationic amino glycoside 
(Perlin et al., 1988) and it has been documented that mutants defective in the “class E” 
of vacuolar protein sorting (Vps) show common phenotype of sensitivity towards 
hygromycin B (Mukherjee et al., 2006). It is believed that the nhx1∆ mutant 
hypersensitivity to hygromycin B results from the defect in sequestration of this cation 
into intracellular compartments (Cagnac et al., 2007; Kinclova-Zimmermannova et al., 
2006).  
Since bleomycin-A5 and polyamines are cations as well, we therefore tested if 
the mutant sensitivity was related to the charge by examining a panel of drugs that are 
both cationic and anionic. We indeed reproduced nhx1∆ mutant sensitivity to 
hygromycin B in YPD media (Fig. 11). Interestingly, the mutant was hypersensitive to 
the anionic drug deoxycholine, as well as to calcofluor white, a related anionic agent 
which interferes with the construction and stress response of the cell wall (Fig. 11) 
(Ram & Klis, 2006). These data suggest that the Nhx1 function is required to prevent 
toxicity caused by a range of charged compounds and not limited to either cationic or 
anionic agents.  
The nhx1∆ mutant was also hypersensitive to two other species of bleomycin, 
bleomycin-A2 and bleomycin-B2, which lack the polyamine moiety (Fig. 11). Thus, it 
is unlikely that the initial sensitivity observed for nhx1∆ mutant towards bleomycin is 
related to the polyamine moiety.  
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Taken together, these data suggest that nhx1∆ mutant shows sensitivity to the 
drugs which are detoxified via endocytic pathway. At this point, the structure or 
charges of the drugs do not play a crucial role. 
 
 
 
 
 
 
 
Figure 11. nhx1∆ mutant displays wide sensitivity towards various drugs. 
Cells were spotted on YPD plates without and with the indicated concentration of 
hygromycin B, calcofluor white, deoxycholic acid or BLM-A2 and photographed as in 
Fig. 7 after 48 h of incubation at 30ºC.  The data is representative of three independent 
analyses. 
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3.4 nhx1∆ mutant exhibits no sensitivity to UV irradiation.  
Since bleomycin is known to damage the DNA and to be detoxified via the 
endocytic machinery (Aouida et al., 2004b), we checked if the nhx1∆ mutant would be 
sensitive to the other DNA damaging agents which are not detoxified through the 
endosomal pathway. Alternatively, we were interested to detect whether the increased 
sensitivity of nhx1∆ mutant to the DNA damaging agents could be partially due to a 
defect in mechanism(s) apart from those involved in vacuolar sequestration of the 
cytotoxic agents. In comparison to the parent, the nhx1∆ mutant showed no additional 
sensitivity to 254-nm ultraviolet light, which creates pyrimidine dimers (Fig. 12) (Gale 
et al., 1987). Thus, it would appear that the drugs which are known to be detoxified via 
the endosomal pathway can cause sensitivity to the nhx1∆ mutant, consistent with the 
identification of Nhx1 as a prevacuolar protein involved in endocytic pathway (Nass & 
Rao, 1998). It has been documented that the mutants defective in V-ATPase activity of 
the vacuole (vma6∆, vma8∆) show sensitivity to UV irradiation (Liao et al., 2007). 
Although V-ATPase activity of the vacuole is required to protect the cells against UV 
irradiation, our data showed that Nhx1 is not involved in limiting the effect of UV 
irradiation. We concluded that the nhx1∆ mutant exhibits sensitivity to DNA damaging 
agents which are detoxified only via endocytic pathway. 
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Figure 12. nhx1∆ mutant exhibits parental sensitivity towards UVC.  
Cells were treated as described in “Materials and methods”. The data are the average of 
three independent experiments. 
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3.5 nhx1∆ mutant is not sensitive to pH and NaCl when grown in 
YPD media 
Mutants defective in vacuolar membrane H+-ATPase activity such as vma12∆ 
are unable to grow on solid YPD media with increasing pH (Hirata et al., 1993). Since 
it has been reported that nhx1∆ mutant has a defect in maintaining the intracellular pH 
in the vacuole and cytoplasm under the special growth media APG, which has a low 
osmolarity and acidic pH (Brett et al., 2005), we therefore tested if the mutant can grow 
on YPD media with varying pH. Like the parent, the nhx1∆ mutant was able to grow 
and tolerate a wide range of pH (pH 4 to 8) (Fig. 13). In contrast, the vacuolar defective 
mutant vma12∆ was unable to grow efficiently at the higher pH (Fig. 13) (Hirata et al., 
1993). Thus, under this growth condition Nhx1 does not appear to play a key role in 
maintaining the vacuolar pH, although the previous report showing nhx1∆ mutant  
sensitivity to pH may be related to the specific growth media, APG (Brett et al., 2005). 
nhx1∆ mutant was reported to be sensitive to NaCl when grown on APG media 
(Brett et al., 2005; Wells & Rao, 2001). However, we found no sensitivity of the nhx1∆ 
mutant to NaCl when grown on YPD (Fig. 14). In fact, the nhx1∆ mutant exhibited 
sensitivity to CaCl2, but not to LiCl or NaCl, when grown on solid YPD media (Fig. 14).  
We did not perform any analysis for drug sensitivity with the APG media, as the 
mutant exhibited sensitivity to hygromycin B whether grown in APG or YPD media. 
Thus, the reported NaCl sensitivity of the nhx1∆ mutant is specifically related to the 
APG media. 
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Figure 13. Effect of pH on nhx1∆ mutant sensitivity 
Exponentially growing cultures of the strains were serially diluted and 5 µl spotted onto 
YPD solid media adjusted to the indicated pH. Plates were photographed after 48 h 
incubation at 30°C.  The data is representative of two independent analyses. 
 
 
 
Figure 14. nhx1∆ mutant displays sensitivity towards CaCl2 but not to NaCl. NaCl, 
CaCl2 and LiCl sensitivity of wild-type or mutant strains were assayed as described for 
Fig. 7. The data is representative of two independent analyses.  
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3.6 Deletion of NHX1 gene does not affect vacuolar acidification. 
To further examine if the nhx1∆ mutant has a defect in vacuolar acidification, 
we tested if the vital dye quinacrine can accumulate in the vacuole. Quinacrine is a 
basic dye that accumulates in acidic compartments in living yeast cells and is used to 
rapidly monitor vacuolar acidification (Weisman et al., 1987). No defect was observed 
in the accumulation of quinacrine into the vacuoles of the nhx1∆ mutant, as compared 
to the parent (Fig. 15). These data confirm that the vacuole was acidified and 
functional. Consistent with this observation it has been shown that blocking 
endocytosis in end4∆ mutant does not affect vacuolar acidification (Plant et al., 1999). 
Thus, it would appear that the sensitivity of the nhx1∆ mutant to the drugs is likely 
unrelated to the maintenance of vacuolar pH.  
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Figure 15. Positive staining of the vital dye quinacrine in the nhx1∆ mutant.  
Vacuolar acidification in living cells; parent strain (A and B) and nhx1∆ mutant (C and 
D) were assessed by visualizing quinacrine accumulation in this organelle as described 
in “Materials and methods”. Figure showed both the bright field (A and C) and 
fluorescent (B and D) images.  The data is representative of three independent analyses. 
 
 
 
 
 
3.7 NaCl does not prevent the toxic effect of bleomycin in nhx1∆ 
mutant. 
Since Nhx1 is a Na+ antiporter involved in sequestration of this ion (Nass et al., 
1997; Nass & Rao, 1998), we tested if nhx1∆ mutant sensitivity to bleomycin could be 
suppressed by adding NaCl to the media. Spot test analysis revealed that addition of 
NaCl does not rescue nhx1∆ mutant sensitivity to bleomycin (Fig. 16). rad52∆ mutant 
which is defective in repair of double-stranded breaks (DSBs) (Symington, 2002) was 
used as control for two reasons: (i) It is sensitive to bleomycin (Keszenman et al., 1992), 
and (ii) It is not affected by varying in concentration of NaCl. It is noteworthy that 
bleomycin loses its genotoxic effect in higher concentration of NaCl (150 mM) (Fig. 
16). The same results were obtained when NaCl was added to Hygromycin B (data not 
shown). These data suggest that drug-phenotype displayed by the nhx1∆ mutant is not 
due to Na+ deficiency. 
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Figure 16: Bleomycin sensitivity of nhx1∆ mutant is not inhibited by NaCl. 
Exponentially cultures were serially diluted and spotted in absence or presence of 
indicated concentration of NaCl and BLM. rad52∆ mutant was used as control. 
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3.8 CPY secretion by the nhx1∆ mutant is not blocked by varying the 
pH or NaCl concentrations. 
nhx1∆ mutant has been documented to secrete carboxypeptidase Y (CPY) (Ali 
et al., 2004). If nhx1∆ mutant phenotypes such as CPY secretion are associated with a 
defect in maintaining the pH of the prevacuolar compartment, then culturing cells in 
low pH is likely to block CPY secretion. In this experiment, the cells were grown in a 
range of pH under minimal media and tested for CPY secretion using nitrocellulose lift 
that was probed with anti-CPY antibodies. Interestingly, the low pH did not prevent 
CPY secretion by the nhx1∆ mutant, while introduction of the pNHX1 plasmid into the 
mutant inhibited the secretion (Fig. 17A).  
We also checked if the CPY secretion could be blocked by increasing NaCl 
concentration. However, we found that increasing NaCl concentrations also did not 
suppress CPY secretion (Fig. 17B). These data raise the possibility that Nhx1 may 
execute an additional function that is crucial to prevent CPY secretion. 
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Figure 17: CPY secretion by the nhx1∆ mutant is not inhibited by varying either 
the pH or NaCl concentrations.  
Exponentially growing cells OD600 ~0.6 were serially diluted, spotted onto 
nitrocellulose membrane followed by incubation of the membrane on top of: A, SD 
media with varying pH, B, YPD media with increasing NaCl concentrations. After 
incubating the plates at 30°C for 12-18 h, the membranes were subjected to 
immunoblotting with mouse anti-CPY. The data is representative of three independent 
analyses. CPY secretion is blocked by introduction of the pNHX1 plasmid into the 
mutant. vps27∆ mutant was used as control. 
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3.9 The Nhx1 variant E355A, but not E371A, is unable to rescue the 
drug phenotype of nhx1∆ mutant. 
 To examine if Nhx1 plays a functional or structural role in protecting cells 
against drug toxicity, we introduced into the nhx1∆ mutant a plasmid expressing either 
Glu355Ala (E355A) or Glu371Ala (E371A) variant of Nhx1. Both variants are located 
on an extracellular loop (H10) that is flanked by two transmembrane helices predicted 
to be inserted into the membrane (Fig. 18) (Mukherjee et al., 2006). Remarkably, the 
mutants were produced and the expression levels of mutant protein were similar to the 
parent strain. Moreover, it has been demonstrated that mutant proteins are localized to 
the late endosome (Mukherjee et al., 2006). While Glu355, but not Glu371, was shown 
to be essential for Nhx1 function in tolerating growth in APG media at low pH 
(Mukherjee et al., 2006), spot test analysis revealed that neither E355A variant nor 
E371A shows sensitivity to varying pH when grown in YPD media (Fig. 19). 
Furthermore, as shown in Fig. 20, the E355A variant did not rescue the nhx1∆ 
sensitivity to either bleomycin or hygromycin B. In contrast, the E371A variant 
complemented these defects to the same extent as the native Nhx1. Taken together, 
these data confirmed that the sensitivity of nhx1∆ mutant or its variants E355A to 
bleomycin or hygromycin B is not due to defect in maintaining intracellular pH under 
the growth on YPD media. Since replacement of the Glu355 residue with neutral 
alanine residue in Nhx1 resulted in sensitivity to bleomycin or hygromycin B as almost 
the same extent as nhx1∆ mutant, it is possible that function rather than structure of the 
exchanger would be critical for drug tolerance. Protein crystallography would figure 
out structural change in E355A and E371A. It is noteworthy that Glu355 residue is 
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invariant among all NHEs (Na+/H+ exchanger) sequences (Mukherjee et al., 2006). 
Therefore, we speculated that E355A substitution in the other NHEs would result in 
sensitivity to bleomycin. 
 
 
 
 
                                        
 
 
 
Figure 18: Predicted topology of Nhx1 
Glu355 and Glu371 in the intramembranous H10 loop of Nhx1 between transmembrane 
segments 9 and 10 are replaced with Ala (Mukherjee et al., 2006). 
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Figure 19: Replacement of the Glu355 or Glu371 residue with neutral Ala residue 
in Nhx1 has no effect on pH sensitivity. 
Exponentially cultures were serially diluted and spotted as in Fig. 13. 
 
 
 
 
Figure 20: The variant E355A, but not E371A, is defective in rescuing nhx1∆ 
mutant from drug toxicities. 
Exponentially cultures were serially diluted and spotted as in Fig. 7. 
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3.10 Nhx1 acts independently of Ypt6 and Ypt7 in drug resistance 
Previous study suggests that Nhx1 and Ypt6 may function along the same 
trafficking pathway as they showed similar sensitivity to hygromycin B in the APG 
media (Ali et al., 2004). As such, we tested if the ypt6∆ mutant would display similar 
sensitivities as nhx1∆ mutant towards various drugs. Surprisingly, although ypt6∆ 
mutant showed hypersensitivity to SPM and calcofluor white, it did not reveal any 
significant sensitivity to bleomycin or hygromycin B on the YPD media (Fig. 21). On 
the basis of these findings, it is unlikely that Nhx1 and Ypt6 are functioning along the 
same pathway in drug detoxification, at least for bleomycin. Interestingly, deletion of 
the YPT6 gene in nhx1∆ mutant resulted in the nhx1∆ ypt6∆ double mutant that was 
more resistant to bleomycin, hygromycin B and SPM (Fig. 22), suggesting that 
accumulation of these drugs in the prevacuole may leak into the Golgi via functional 
Ypt6 which consequently leads to increased cell killing.  
It is noteworthy that the ypt7∆ mutant lacking a protein involved in fusion of the 
vesicles derived from endosomes with the vacuoles (Ali et al., 2004) also did not show 
any significant sensitivity towards either bleomycin or hygromycin B (Fig. 21). This is 
also in contrast to the hygromycin B sensitivity observed for ypt7∆ mutant when tested 
on APG media, suggesting that the type of media might influence the phenotypes 
displayed by these mutants.  
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Figure 21. Comparison of the sensitivities of the parent and the indicated mutants 
towards various drugs.  
Exponentially cultures were serially diluted and spotted as in Fig. 7 
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Figure 22. nhx1∆ ypt6∆ double mutant shows more resistance towards indicated 
drugs when compared to nhx1∆ mutant. 
Exponentially cultures were serially diluted and spotted as in Fig. 7 
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Discussion   
We report novel phenotypes of the nhx1∆ mutant that raise additional 
interesting questions regarding the function of Nhx1. The initial experiments done to 
characterize the physiological role of Nhx1 were performed mainly in APG medium 
with low osmolarity, which is essential in order to reveal the osmotolerance defect and 
to accurately measure the intracellular pH of nhx1∆ mutant (Brett et al., 2005). This 
media was also used to demonstrate that the nhx1∆ mutant is sensitive to NaCl (Brett et 
al., 2005; Wells & Rao, 2001). In accordance with the previous studies, we show that 
the nhx1∆ mutant revealed hypersensitivity to hygromycin B, as well as displayed the 
CPY missorting phenotype even when grown in the rich media YPD. However, under 
the YPD growth media, the nhx1∆ mutant no longer retained sensitivity to NaCl even at 
high concentration (1 M in YPD). Moreover, addition of NaCl to the YPD media did 
not suppress the nhx1∆ sensitivities to any of the drugs (Fig 16). These observations 
clearly uncoupled the drug sensitivities, as well as CPY missorting, from a need to 
maintain osmolarity, suggesting that any deficiency of Na+ in the late endosome can not 
account for the drug phenotypes displayed by the nhx1∆ mutant.  
Another unique observation reported in this study is that neither ypt6∆ mutant 
nor ypt7∆ mutant was sensitive to hygromycin B when grown in YPD media as 
compare to the sensitivity seen with the APG media (Ali et al., 2004). If indeed Nhx1 
and Ypt6 function along the same pathway as proposed (Ali et al., 2004), it is expected 
that ypt6∆ mutant should show at least some level of sensitivity to hygromycin B 
particularly since nhx1∆ mutant is dramatically sensitive to the drug. One explanation 
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for this observation is that under YPD media, an alternative member of the Ypt proteins, 
of which there are at least eleven (Lazar et al., 1997), could be expressed to substitute 
for Ypt6. Likewise, a similar explanation may hold true for the lack of sensitivity of 
ypt7∆ mutant to hygromycin B in YPD media.  
As pointed out above, one of our main interests is to understand how bleomycin 
is detoxified in yeast cells. Our data to date suggest that the key detoxification pathway 
involves the endosomal process, as mutants defective in this pathway are sensitive to 
bleomycin (Aouida et al., 2004b). However, we do not know if the main reason for 
cytotoxicity or genotoxicity is a result of leak from the endosomal process. The data 
presented here would indicate that defect in the late endosome is a major factor leading 
to toxicity. It is possible that the toxicity could arise as a result of drug leak from the 
late endosome to the cytosol or the leak is via retrograde trafficking from the late 
endosome to the nucleus through the Golgi and the endoplasmic reticulum. In the latter 
situation, we would expect that blocking Ypt6 function (involved in recycling of 
cargoes from the late endosome to the Golgi) would cause elevated resistance to 
bleomycin. Instead, we observed that ypt6∆ mutant was only weakly sensitive to 
bleomycin. Therefore, since the endocytic pathway is functional in the ypt6∆ mutant, it 
is unlikely that leak from the late endosome to Golgi is a major contributing factor for 
severe toxicity caused by bleomycin. The modestly increased resistance to bleomycin 
observed when YPT6 is deleted in the nhx1∆ mutant may be due to lack of cargoes 
exchange from prevacuolar compartment to the Golgi. On the other hand, in the 
absence of Nhx1, Ypt6 could play an important role in transporting bleomycin to the 
Golgi which causes bleomycin sensitivity. 
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What could be the role of Nhx1, if it is not involved in osmotolerance or pH 
homeostasis in YPD media? Nhx1 could play a role in mediating the tethering of the 
late endosome to the vacuoles for efficient drug delivery. For example, the HOPS 
complex presented on the vacuoles consists of several proteins and some of which 
could participate in the fusion process with the late endosome, as reported for Ypt7 
which is required for fusion of vesicles derived from endosome with the vacuole, 
through an interaction with the HOPS complex (Ungermann et al., 2000). In this 
manner, the fusion process might occur by tethering of the HOPS protein directly or 
indirectly with Nhx1. Consistent with this notion, Nhx1 has been shown to participate 
in protein-protein interaction whereby its C-terminal tail interacts with Gyp6, an 
activator of the Ypt6 GTPase activity (Ali et al., 2004). However, further studies would 
be needed to clarify if this is the actual mechanism by which Nhx1 functions in drug 
tolerance when cells are grown in YDP media.  
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Conclusion 
On the basis of our study, it is clear that additional studies are needed to 
characterize the role of Nhx1 on drug detoxification, in particular bleomycin, which 
could lead to improve chemotherapeutic response. We draw a model to describe how 
Nhx1 could be involved in protecting the cells against harmful agents. Nhx1 is located 
in prevacuolar compartment which fuses with vacuole to deliver the cargoes for 
degradation. Defect in prevacuolar compartment resulted from NHX1 deletion leads to 
cargoes accumulation in prevacuolar compartment. Since latter compartment does not 
contain the essential enzymes required for cargoes degradation, accumulated cargoes 
might reach to nucleus either directly through cytosol or indirectly via the Golgi. 
Our data showed that when YPT6 is deleted in the nhx1∆ mutant, nhx1∆ 
ypt6∆ double mutant shows more resistance towards bleomycin as compared to 
nhx1∆ mutant. These data could indicate the effect of Ypt6 on bleomycin-induced cells 
killing in the nhx1∆ mutant. If indeed Ypt6 is a major contributing factor in the absence 
of NHX1, we expect that YPT6 overexpression in the nhx1∆ mutant causes more 
sensitivity. Althernativly, YPT6 overexpression would lead to more leaking from 
prevacuolar compartment to the Golgi resulting in increased sensitivity in the nhx1∆ 
mutant. 
Saccharomyces cerevisiae possesses two plasma membrane Na+/H+ antiporters 
(Ena1-4 & Nha1). If drug-phenotype in nhx1∆ mutant is not due to Na+ deficiency, we 
expect that the single ena1-4∆ mutant which is sensitive to NaCl (Kinclova-
Zimmermannova et al., 2006) to show parental sensitivity to bleomycin. In addition, we 
expect that the nhx1∆  ena1-4∆ double mutants to be hypersensitive to NaCl, but retain 
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the same level of sensitivity to bleomycin as the nhx1∆ single mutant. The same 
expectations would be speculated for the single nha1∆ mutant and the nhx1∆ nha1∆ 
double mutants. 
It is noteworthy that Nhx1-related proteins, NHE6, 7, 8 and 9 are present in 
human cells (Nakamura et al., 2005), although it is not known if any of these, when 
knockdown separately, would cause sensitivity to the same class of drugs as the nhx1∆ 
mutant. Perhaps targeting this unique isoform of the human NHEs would provide a way 
of improving the chemotherapeutic benefits of bleomycin.  
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